Gilead Sciences (NYSE:GILD) is a fast-growing biotechnology firm with a dominant market share in treating the HIV virus. This combined with a low double-digit P/E ratio makes it a seeming steal for investors. Unfortunately, patent expirations for its HIV franchise are on the horizon. However, the stock still deserves a further look.

Read the rest of this entry »